Stock screener

RGNX

Conviction 36HealthcareScan · Mon, Aug 10, 2026
RGNX$10.43-2.71%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 1.32M
May 11May 28Jun 16Jul 6Jul 23Aug 10
REGENXBIO Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.regenxbio.com
Price10.43
Change-2.71%
Gap-0.79%
Rel volume1.41×
Avg volume1.75M
Avg $ vol18.2M
SMA 2010.42
SMA 509.95
SMA 20010.52
Price vs 50+4.87%
Price vs 200-0.82%
MA stackmixed
50/200 cross
Supertrenddown · 12.27
RSI (14)49
MACD hist-0.01
MACD cross
Stoch %K / %D54 / 70
ADX (14)20
+DI / −DI25 / 25
RSI divergence
MACD divergence
ATR %+8.31%
ADR %7.21%
52w high15.98
52w low5.65
From 52w high-34.73%
Above 52w low+84.60%
New 52w highNo
SqueezeOff
Bollinger width29.58%
%B0.50
Donchian pos43.89%
Donchian high13.00
Donchian low8.42
AVWAP (52w high)9.49
vs AVWAP high+9.92%
AVWAP (52w low)9.78
vs AVWAP low+6.61%
OBV trendDown
Chaikin MF (20)0.09
Today vs 20d1.41×
Avg vol (14d)1.32M
Avg vol (20d)1.75M
Avg $ vol (20d)18.2M
Market cap688.52M
RS 3m (vs SPY)-2.82%
RS 6m (vs SPY)-9.63%
RS line new highNo
Trend template2/8
Technical rank40.0
1 week+4.72%
1 month-25.23%
3 months-1.14%
6 months+0.97%
1 year+32.03%
YTD-23.14%
P/E-3.55
P/B9.59
P/S4.04
P/FCF-5.45
EPS-3.76
Div yield
ROE-270.16%
ROA-50.15%
Debt/Eq
Current2.86
EV/EBITDA-4.48
Gross margin
Net margin-113.75%
Rev growth104.54%
EPS growth14.63%
Price target23.30
Target upside123.39%
Analyst ratingBuy
Institutional70.03%
Ent. value652.03M
Revenue108.02M
Net income22.71M
Gross profit
Free cash flow-126.38M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out51.7M
Employees371
ListedThu, Sep 17, 2015
Free float38.66M
Float %74.9%
Short interest8.63M
Days to cover3.3d
Short volume43.1%
Squeeze score65 / 100
Next earnings
EPS forecast
Last EPS vs est$0.43 vs $0.12
Last surprise+258.3% beat
Setup gradeD
Conviction36 / 100
Pattern quality
Tech rank40.0 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance13.69
Support8.80
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RGNX

All disclosures →
No recent disclosed trades by Congress in RGNX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RGNX · 10 buys

InsiderSideShares
Bennett Jean
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Tasse Daniel
Director · Common Stock · 2026-05-29
Grant9.81K
Zachary Jennifer
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Glucksmann Alexandra
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
KARABELAS ARGERIS N
Director · Common Stock · 2026-05-29
Grant9.81K
Glucksmann Alexandra
Director · Common Stock · 2026-05-29
Grant9.81K
Tasse Daniel
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Zachary Jennifer
Director · Common Stock · 2026-05-29
Grant9.81K
Fox Allan M.
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
KARABELAS ARGERIS N
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K

SEC filings

EDGAR filings in RGNX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.